These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 25824776)

  • 1. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating
    Hu Y; Cui J; Jin L; Su Y; Zhang X
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
    Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
    Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.
    Gao ZJ; Yuan WD; Yuan JQ; Yuan K; Wang Y
    Med Sci Monit; 2018 Feb; 24():1104-1111. PubMed ID: 29469087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells.
    Lei X; Huang Z; Zhong M; Zhu B; Tang S; Liao D
    Acta Biochim Biophys Sin (Shanghai); 2007 May; 39(5):344-50. PubMed ID: 17492131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
    Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
    Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
    Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
    Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
    Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
    Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.